Serum apelin levels and cardiovascular diseases

Apelin is a G protein-linked receptor endogenous ligand, synthesized as a 77-amino acid pre-propeptide. Increased expression of apelin is present in many cardiovascular (CV) tissues, including cardiomyocytes. It is a peripheral vasodilator and one of the most potent stimulants of ventricular contraction. Apelin may be a valuable therapeutic for both blood pressure regulation and myocardial performance. More information is needed for the CV pathophysiology of apelin. We will discuss the importance of apelin level in CV diseases in this review.

🔖

Bu Makaleye Atıf Yap

AŞKIN, L., Özyıldız, A. G., DUMAN, H., TANRIVERDİ, O., AŞKIN, H. Ş. (2022). Serum apelin levels and cardiovascular diseases. İstanbul Kuzey Klinikleri, Cilt: 9 - Sayı: 3, 290–294. https://ajindex.com/articles/551219

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

Hou X, Zeng H, He X, Chen JX. Sirt3 is essential for apelin-induced angiogenesis in post-myocardial infarction of diabetes. J Cell Mol Med 2015;19:53–61
Li L, Zeng H, Hou X, He X, Chen JX. Myocardial injection of apelin-overexpressing bone marrow cells improves cardiac repair via upregulation of Sirt3 after myocardial infarction. PLoS One 2013;8:e71041
Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 2006;553:222–8
Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006;8:355–60
Hou X, Hu Z, Xu H, Xu J, Zhang S, Zhong Y, et al. Advanced glycation endproducts trigger autophagy in cadiomyocyte via RAGE/PI3K/ AKT/mTOR pathway. Cardiovasc Diabetol 2014;13:78
Jia YX, Pan CS, Zhang J, Geng B, Zhao J, Gerns H, et al. Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept 2006;133:147–54
Liu HT, Chen M, Yu J, Li WJ, Tao L, Li Y, et al. Serum apelin level predicts the major adverse cardiac events in patients with ST elevation myocardial infarction receiving percutaneous coronary intervention. Medicine (Baltimore) 2015;94:e449
Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009;54:598–604
Yi L, Hou X, Zhou J, Xu L, Ouyang Q, Liang H, et al. HIF-1α genetic variants and protein expression confer the susceptibility and prognosis of gliomas. Neuromolecular Med 2014;16:578–86
Hou X, Hu Z, Huang X, Chen Y, He X, Xu H, et al. Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients. J Mol Med (Berl) 2014;92:487–95
Tycinska AM, Sobkowicz B, Mroczko B, Sawicki R, Musial WJ, Dobrzycki S, et al. The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction. Clin Chim Acta 2010;411:2014–8
Kuklinska AM, Sobkowicz B, Sawicki R, Musial WJ, Waszkiewicz E, Bolinska S, et al. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart Vessels 2010;25:363–7
Zhang BH, Guo CX, Wang HX, Lu LQ, Wang YJ, Zhang LK, et al. Cardioprotective effects of adipokine apelin on myocardial infarction. Heart Vessels 2014;29:679–89
Japp AG, Newby D